Friday, November 21, 2014 12:11:52 PM
What this means to me is: (reading the tea leaves)
1. He has stated that does not see a need to dilute at this price point. What can this mean? Leo is looking at the full data set and believes Brilacidin is as good or better than the best drugs (Dapto) on the market and vastly superior to Durata which was just purchased for more that 600,000,000.
2. He has stated he would like to up-list to a sr. market, yet why hasn't he moved to the NYSE MRK (or other similar markets)? IMO, he most likely feels that he is close to having what he needs for a move to his target market, the NASDAQ, in the near to mid term (2015). Again, he knows the bottom line Brilacidin data which gives him confidence and understanding we sometime don't have.
3. No independent BoD members yet, why not? Leo has done very well without a BoD and adding additional egos, cost and oversight, while necessary in the long run, may not be the best course in the short term (1-3 months). When the B PIIa bottom line results are made public, he must feel that the market and potential Board members will take note and that the company will be ready to become more mature.
4. Brilacidin Phase III, it took Leo little more than a year to buy a completely novel technology (drug) platform and build, submit, finish and analyses a phase II trial. The trial itself was only about six months long. I think Leo expects multiple phase III Brilacidin trials to start and end in 2015.
5. Proving of Defensin Mimetics as a real and novel class of antibiotics. This is new ground and it will take scientists and regulators time to understand and accept the new platform.
All of the items above focus on Brilacidin progress. We have two other compounds that may prove as big or bigger than Brilacidin. I have a HUGE investment in CTIX and while it is risky, the risk profile is as good as I've ever seen for a public company. It really is akin to investing in a google/FB type play in a series A/B round.
If any of the PIII trials of Brilacidin are successful in 2015, CTIX will have a market cap in the 3-5B range (roughly 10-20x higher than our current stock price).
Again, this is a long term buy on the dips and hold. I hope everyone has a great holiday week. I know I'll be hitting some beaches and getting out of the cold and snow!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM